Foresight Diagnostics and Roche Molecular Systems have resolved ongoing litigation related to PhasED-Seq sequencing technology through a limited licensing agreement. The deal grants Roche a royalty-bearing sublicense to develop in vitro diagnostic kits for non-Hodgkin’s lymphoma, ending trade secret allegations. Intellectual property rights remain with Stanford University, and Foresight retains exclusivity for all other uses. The resolution allows both companies to focus on advancing cancer diagnostic solutions.